semaglutide wellesley Semaglutide: A Breakthrough in Weight Management Semaglutide | DirectMeds

Description

doi: 10.1200/jco.2011.41.0936

Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial

Discussion Semaglutide received Food and Drug Administration approval in 2017 for the management of type 2 diabetes and was later approved in 2021 for weight management

Most patients begin tirzepatide at the lowest dose (2.5 mg weekly injection or equivalent oral dose) regardless of their prior semaglutide strength, allowing the new dual-pathway system to establish baseline tolerance